Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study

By sjmartinez • February 20, 2025

Duivon M, Christy F, Thomas E, Lequesne J, Castel H, Gaudin C, Delmas D, Boyault S, Rigal O, Bousrih C, Lévy C, Lerebours F, Di Meglio A, Ganz PA, Van Dyk K, Vaz Luis I, Lange M, Joly F. Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study. Breast Cancer Res. 2025 Feb 19;27(1):25. doi: 10.1186/s13058-025-01974-2. PMID: 39972319; PMCID: PMC11841345.

Tags: APOE4, breast cancer, Cancer-related cognitive impairment, chemotherapy, Endocrine therapy, Hematology/Oncology, Publications

Related Posts

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike[...]

Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351)

Ngo D, Kaleka G, Yang D, Mokhtari S, Tinajero J, Marcucci G, Nakamura R, Pullarkat V, Oliai C, Salhotra A. Real world outcomes of patients[...]

Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study

Rogers KA, Yan P, Flinn IW, Stephens DM, Kipps TJ, Larson SM, Martz L, Chen X, Wang H, Hopping E, Bundschuh R, Turkoglu A, Lozanski[...]